Evoke Pharma (EVOK) Environmental, Social & Governance (ESG) Data

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

External links

Employees

Data from SEC filings

Employee count

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Environment Extreme Weather Intensity Lifecycle Materials Natural Resources Nature Offset Package Packaging Pandemic Raw Materials Water Wind Access Benefits Black California Consumer Privacy Act Citizenship Collective Bargaining Community Customer Cybersecurity Data Privacy Data Security Death Disability Diversity Drug Pricing Employee Engagement Gender General Data Protection Regulation Health Care Healthcare Hire Hiring Human Capital Human Resources Incident Injury Opioid Overtime Perquisites Privacy Recall Recruitment Reimbursement Retention Retirement Safety Satisfaction Skills Social Society Supplier Training Union Women Assessment Assurance Attorney General Audit Bonus Chronic Class Action Lawsuit Classified Clawback Commitment Conflict of Interest Corporate Governance Corporate Purpose Department of Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Incentivize Independence Independent Innovation Innovative Investigation Lawsuit Leadership Litigation Long-term Majority Oversee Oversight Perquisite Proxy Access Purpose Quality Standard R&D Reputation Reputational Risk Research and Development Responsibility Responsible Special Meeting Strategy Sustainable Targets Tax Transparency Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

The Company held its Annual Meeting solely by means of remote communication through a live webcast on May 10, 2023, at 8:30 a.m., Pacific Time. As of the close of business on March 13, 2023, the record date for the Annual Meeting, there were 3,343,070 shares of common stock entitled to vote, of which there were 1,844,591 shares present at the Annual Meeting in person or by proxy. At the Annual Meeting, stockholders voted on seven matters: (i) the election of two Class I Directors for a term of three years expiring at the 2026 Annual Meeting of Stockholders; (ii) the ratification of the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023; (iii) the approval of, on an advisory basis, the compensation of the Company’s named executive officers; (iv) the approval of the amendment and restatement of the Company’s 2013 Equity Incentive Award Plan; (v) the approval of the amendment and restatement of the Company’s 2013 Employee Stock Purchase Plan; (vi) the approval of the Amendment to increase the authorized number of shares of common stock from 50,000,000 to 100,000,000, and (vii) the approval of the Amendment to update the exculpation provision to include certain officers of the Company as permitted by a recent amendment to Delaware law. The results of the voting were as follows:

•Election of two Class I Directors for a term of three years expiring at the 2026 Annual Meeting of Stockholders:


Kenneth J. Widder, M.D.	For	640,351	Withheld	200,558
David A. Gonyer, R. Ph.	For	615,466	Withheld	225,444

There were 1,003,680 broker non-votes related to each of the two director nominees for election. The two nominees for Class I Director were elected.

•Ratification of the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023:

Shares Voted For 1,608,564 Against 210,378 Abstain 25,648

There were no broker non-votes related to the appointment of BDO USA, LLP.The appointment of BDO USA, LLP was ratified.

•The approval of, on an advisory basis, the compensation of the Company’s named executive officers:

Shares Voted For 449,722 Against 351,948 Abstain 39,240

There were 1,003,680 broker non-votes related to the compensation of our named executive officers. The foregoing proposal was approved.

•The approval of the amendment and restatement of the Company’s 2013 Equity Incentive Award Plan:

Shares Voted For 419,933 Against 392,263 Abstain 28,713

There were 1,003,680 broker non-votes related to the approval of the amendment and restatement of the Company’s 2013 Equity Incentive Award Plan.The foregoing proposal was approved.

•The approval of the amendment and restatement of the Company’s 2013 Employee Stock Purchase Plan

Shares Voted For 423,621 Against 361,699 Abstain 55,589

There were 1,003,680 broker non-votes related to the amendment and restatement of the Company’s 2013 Employee Stock Purchase Plan. The foregoing proposal was approved.

•The approval of the Amendment to increase the authorized number of shares of common stock from 50,000,000 to 100,000,000:

Shares Voted For 1,199,246 Against 638,835 Abstain 6,509

There were no broker non-votes related to the Amendment to increase the authorized number of shares of common stock from 50,000,000 to 100,000,000. The foregoing proposal required a majority of our outstanding shares of common stock and, therefore, was not approved.

•The approval of the Amendment to update the exculpation provision to include certain officers of the Company as permitted by a recent amendment to Delaware law:

Shares Voted For 578,518 Against 248,369 Abstain 14,023

There were 1,003,680 broker non-votes related to the Amendment to update the exculpation provision to include certain officers of the Company as permitted by a recent amendment to Delaware law. The foregoing proposal required a majority of our outstanding shares of common stock and, therefore, was not approved.